Korean J Dermatol.
2009 Jun;47(6):739-742.
A Case of Bullous Fixed Drug Eruption Coexisting with Hand-Foot Syndrome and This Was Induced by Sunitinib
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Kyunghee University, Seoul, Korea. nikim@khmc.or.kr
Abstract
- Sunitinib is multitargeted tyrosine kinase inhibitor, and this drug was approved for use to treat gastrointestinal stromal tumor and advanced renal cell carcinoma. It has also been shown to be efficacious in treating neuroendocrine, colon and breast cancer. Sunitinib therapy is often complicated by cutaneous adverse effects such as hand-foot syndrome, hair depigmentation, subungal splinter hemorrhage, xerosis, alopecia and seborrheic dermatitis- like reactions. But there have been no reports on patients presenting with a bullous fixed drug eruption associated with sunitinib administration. We report here on a case of a bullous fixed drug eruption and hand-foot syndrome, and these maladies were caused by this agent.
